Prophylactic Staphylococcus aureus subunit vaccine shows promising results

22-Dec-2006

Intercell AG has been informed by its strategic partner Merck & Co., Inc. that a Phase I study of a recombinant subunit vaccine to prevent Staphylococcus aureus infections is progressing with promising results. The vaccine is based on a conserved protein antigen discovered by Intercell's Antigen Identification Program (AIP®) and licensed to Merck & Co., Inc. on an exclusive world wide basis in 2003.

"The fact that a vaccine based on our antigen discovery platform has delivered promising data in humans underlines the scientific and commercial potential of Intercell's technology platforms", states Alexander von Gabain, CSO of Intercell. "It is our strategy to develop our own vaccine candidates based on our technologies, and also to partner with the best players in the field to create significant value."

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...